Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation
Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., announced it is advancing its novel, potentially first-in-class…
Read More...
Read More...
